Battle of Saint-Fulgent

Fulgent Reports Third Quarter 2023 Financial Results

Retrieved on:

Friday, November 3, 2023

Fulgent Genetics, Inc. (NASDAQ: FLGT) (“Fulgent” or the “Company”), a technology-based company with a well-established clinical diagnostic business and a therapeutic development business, today announced financial results for its third quarter ended September 30, 2023.

Key Points:

Fulgent Genetics, Inc. (NASDAQ: FLGT) (“Fulgent” or the “Company”), a technology-based company with a well-established clinical diagnostic business and a therapeutic development business, today announced financial results for its third quarter ended September 30, 2023.
Fulgent will host a conference call for the investment community today at 8:30 AM ET (5:30 AM PT) to discuss its third quarter 2023 results.
Management uses these non-GAAP financial measures along with the most directly comparable GAAP financial measure of net income (loss) in evaluating the Company’s operating performance.
Non-GAAP financial measures should not be considered in isolation from, or as a substitute for, financial information presented in conformity with GAAP, and non-GAAP financial measures as reported by Fulgent may not be comparable to similarly titled metrics reported by other companies.

Fulgent Reports Second Quarter 2023 Financial Results

Retrieved on:

Friday, August 4, 2023

Fulgent Genetics, Inc. (NASDAQ: FLGT) (“Fulgent” or the “Company”), a technology-based company with a well-established clinical diagnostic business and a therapeutic development business, today announced financial results for its second quarter ended June 30, 2023.

Key Points:

Fulgent Genetics, Inc. (NASDAQ: FLGT) (“Fulgent” or the “Company”), a technology-based company with a well-established clinical diagnostic business and a therapeutic development business, today announced financial results for its second quarter ended June 30, 2023.
Non-GAAP income (loss), non-GAAP income (loss) per share, and adjusted EBITDA income (loss) are described below under “Note Regarding Non-GAAP Financial Measures” and are reconciled to the most directly comparable GAAP financial measure, GAAP income (loss), in the accompanying tables.
Our current cash position enables us to continue investing in our business.”
For the third quarter of 2023, Fulgent expects:
For the full year 2023, Fulgent now expects:
Fulgent will host a conference call for the investment community today at 8:30 AM ET (5:30 AM PT) to discuss its second quarter 2023 results.
Non-GAAP financial measures should not be considered in isolation from, or as a substitute for, financial information presented in conformity with GAAP, and non-GAAP financial measures as reported by Fulgent may not be comparable to similarly titled metrics reported by other companies.

Fulgent Reports First Quarter 2023 Financial Results

Retrieved on:

Friday, May 5, 2023

Fulgent Genetics, Inc. (NASDAQ: FLGT) (“Fulgent” or the “Company”), a technology-based company with a well-established clinical diagnostic business and a therapeutic development business, today announced financial results for its first quarter ended March 31, 2023.

Key Points:

Fulgent Genetics, Inc. (NASDAQ: FLGT) (“Fulgent” or the “Company”), a technology-based company with a well-established clinical diagnostic business and a therapeutic development business, today announced financial results for its first quarter ended March 31, 2023.
Non-GAAP income (loss), non-GAAP income (loss) per share, and adjusted EBITDA income (loss) are described below under “Note Regarding Non-GAAP Financial Measures” and are reconciled to the most directly comparable GAAP financial measure, GAAP income (loss), in the accompanying tables.
Our cash position continues to afford us the flexibility to be opportunistic and strategic in building a sustainable business for the long-term.”
For the second quarter of 2023, Fulgent expects:
For the full year 2023, Fulgent now expects:
Fulgent will host a conference call for the investment community today at 8:30 AM ET (5:30 AM PT) to discuss its first quarter 2023 results.
Non-GAAP financial measures should not be considered in isolation from, or as a substitute for, financial information presented in conformity with GAAP, and non-GAAP financial measures as reported by Fulgent may not be comparable to similarly titled metrics reported by other companies.

Fulgent Reports Fourth Quarter and Full Year 2022 Financial Results

Retrieved on:

Tuesday, February 28, 2023

Fulgent Genetics, Inc. (NASDAQ: FLGT) (“Fulgent”, or the “Company”), a technology-based company with a well-established clinical diagnostic business and a therapeutic development business, today announced financial results for its fourth quarter and full year ended December 31, 2022.

Key Points:

Fulgent Genetics, Inc. (NASDAQ: FLGT) (“Fulgent”, or the “Company”), a technology-based company with a well-established clinical diagnostic business and a therapeutic development business, today announced financial results for its fourth quarter and full year ended December 31, 2022.
Non-GAAP income (loss), non-GAAP income (loss) per share, and adjusted EBITDA income (loss) are described below under “Note Regarding Non-GAAP Financial Measures” and are reconciled to the most directly comparable GAAP financial measure, GAAP income (loss), in the accompanying tables.
Certain information set forth in this press release, including non-GAAP income (loss), non-GAAP income (loss) per share, and adjusted EBITDA income (loss) are non-GAAP financial measures.
Management uses these non-GAAP financial measures along with the most directly comparable GAAP financial measure of net income (loss) in evaluating the Company's operating performance.

CONTINUED INVESTIGATION ALERT REMINDER: Scott+Scott Attorneys at Law LLP Investigates Fulgent Genetics, Inc.’s Directors and Officers for Breach of Fiduciary Duties – FLGT

Retrieved on:

Wednesday, January 18, 2023

News, Genetics, U.S. Department of Justice Office of Legislative Affairs, Stark Law, Anti-Kickback Statute, Privacy Office of the U.S. Department of Homeland Security, Remuneration, Justice, Battle of Saint-Fulgent, Stark, Disclosure, Law, Pharmaceutical industry

NEW YORK, Jan. 18, 2023 (GLOBE NEWSWIRE) -- Scott+Scott Attorneys at Law LLP (“Scott+Scott”), an international securities and consumer rights litigation firm, reminds investors of its continued investigation of certain directors and officers of Fulgent Genetics, Inc. (“Fulgent”) (NASDAQ: FLGT) for breaching their fiduciary duties to Fulgent and its shareholders.

Key Points:

NEW YORK, Jan. 18, 2023 (GLOBE NEWSWIRE) -- Scott+Scott Attorneys at Law LLP (“Scott+Scott”), an international securities and consumer rights litigation firm, reminds investors of its continued investigation of certain directors and officers of Fulgent Genetics, Inc. (“Fulgent”) (NASDAQ: FLGT) for breaching their fiduciary duties to Fulgent and its shareholders.
If you are a Fulgent shareholder, you may contact attorney Joe Pettigrew for additional information toll-free at 844-818-6982 or [email protected] .
If you are a Fulgent shareholder, you may have legal claims against Fulgent’s directors and officers.
If you wish to discuss this investigation, or have questions about this notice or your legal rights, please contact attorney Joe Pettigrew toll-free at 844-818-6982 or [email protected] .

INVESTIGATION ALERT REMINDER: Scott+Scott Attorneys at Law LLP Investigates Fulgent Genetics, Inc.’s Directors and Officers for Breach of Fiduciary Duties – FLGT

Retrieved on:

Tuesday, January 10, 2023

Class Action Lawsuit, Professional Services, Legal, News, Genetics, U.S. Department of Justice Office of Legislative Affairs, Stark Law, Anti-Kickback Statute, Privacy Office of the U.S. Department of Homeland Security, Remuneration, Justice, Battle of Saint-Fulgent, Stark, Disclosure, Law, Pharmaceutical industry

Scott+Scott Attorneys at Law LLP (“Scott+Scott”), an international securities and consumer rights litigation firm, reminds investors of its continued investigation of certain directors and officers of Fulgent Genetics, Inc. (“Fulgent”) (NASDAQ: FLGT) for breaching their fiduciary duties to Fulgent and its shareholders.

Key Points:

Scott+Scott Attorneys at Law LLP (“Scott+Scott”), an international securities and consumer rights litigation firm, reminds investors of its continued investigation of certain directors and officers of Fulgent Genetics, Inc. (“Fulgent”) (NASDAQ: FLGT) for breaching their fiduciary duties to Fulgent and its shareholders.
If you are a Fulgent shareholder, you may contact attorney Joe Pettigrew for additional information toll-free at 844-818-6982 or [email protected] .
If you are a Fulgent shareholder, you may have legal claims against Fulgent’s directors and officers.
If you wish to discuss this investigation, or have questions about this notice or your legal rights, please contact attorney Joe Pettigrew toll-free at 844-818-6982 or [email protected] .

FULGENT ALERT: Bragar Eagel & Squire, P.C. is Investigating Fulgent Genetics, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm

Retrieved on:

Saturday, January 14, 2023

News, Genetics, U.S. Department of Justice Office of Legislative Affairs, Anti-Kickback Statute, Privacy Office of the U.S. Department of Homeland Security, Remuneration, Justice, Telephone, Stark, Disclosure, P.C, Battle of Saint-Fulgent

NEW YORK, Jan. 13, 2023 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against Fulgent Genetics, Inc. (NASDAQ: FLGT) on behalf of long-term stockholders following a class action complaint that was filed against Fulgent on September 20, 2022 with a Class Period from March 22, 2019 to August 4, 2022.

Key Points:

NEW YORK, Jan. 13, 2023 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against Fulgent Genetics, Inc. (NASDAQ: FLGT) on behalf of long-term stockholders following a class action complaint that was filed against Fulgent on September 20, 2022 with a Class Period from March 22, 2019 to August 4, 2022.
Our investigation concerns whether the board of directors of Fulgent have breached their fiduciary duties to the company.
On August 4, 2022, Fulgent released its second quarter 2022 financial results, disclosing that the SEC was conducting an investigation into certain of Fulgent’s reports filed with the SEC from 2018 through the first quarter 2020.
There is no cost or obligation to you.

Barrack, Rodos & Bacine (BR&B) Is Investigating Fulgent Genetics Inc. (NASDAQ: FLGT) For Potential Investor Claims

Retrieved on:

Tuesday, December 27, 2022

Linda, McKesson Corporation, Fraud, MCI Inc., BR, Acquisition, Cendant, AIG, Genetics, Battle of Saint-Fulgent, History

PHILADELPHIA, Dec. 27, 2022 (GLOBE NEWSWIRE) -- Barrack, Rodos & Bacine (BR&B) is investigating Fulgent Genetics Inc. based on issues arising from its recent acquisitions, including the acquisition of Fulgent Pharma LLC, a wholly owned subsidiary of Fulgent Pharma Holdings, which itself is wholly-owned by Ming Hsieh (Fulgent Genetic’s President and CEO) and a related Hsieh Trust that he controls.

Key Points:

PHILADELPHIA, Dec. 27, 2022 (GLOBE NEWSWIRE) -- Barrack, Rodos & Bacine (BR&B) is investigating Fulgent Genetics Inc. based on issues arising from its recent acquisitions, including the acquisition of Fulgent Pharma LLC, a wholly owned subsidiary of Fulgent Pharma Holdings, which itself is wholly-owned by Ming Hsieh (Fulgent Genetic’s President and CEO) and a related Hsieh Trust that he controls.
BR&B is also investigating the recent resignations of several members of Fulgent Genetics’ Board and certain stock transactions made by CEO Hsieh over the past few years.
If you are a Fulgent Genetics shareholder, you are encouraged to contact Mark Stein or Linda Border at Barrack, Rodos & Bacine, at the toll-free number 877-386-3304, or via email at [email protected] or [email protected] , to learn more about the firm’s investigation and your legal rights and options.
The firm's largest recoveries on behalf of investors include $6.19 billion for WorldCom investors, $3.32 billion for Cendant investors, $1.05 billion for McKesson investors, and $970.5 million for AIG investors.

INVESTIGATION ALERT: Scott+Scott Attorneys at Law LLP Investigates Fulgent Genetics, Inc.’s Directors and Officers for Breach of Fiduciary Duties – FLGT

Retrieved on:

Monday, November 28, 2022

Class Action Lawsuit, Professional Services, Legal, U.S. Department of Justice Office of Legislative Affairs, Disclosure, Law, Stark, Stark Law, Genetics, Battle of Saint-Fulgent, Privacy Office of the U.S. Department of Homeland Security, News, Anti-Kickback Statute, Justice, Remuneration, Pharmaceutical industry

Scott+Scott Attorneys at Law LLP (Scott+Scott), an international securities and consumer rights litigation firm, is investigating certain directors and officers of Fulgent Genetics, Inc. (Fulgent) (NASDAQ: FLGT) for breaching their fiduciary duties to Fulgent and its shareholders.

Key Points:

Scott+Scott Attorneys at Law LLP (Scott+Scott), an international securities and consumer rights litigation firm, is investigating certain directors and officers of Fulgent Genetics, Inc. (Fulgent) (NASDAQ: FLGT) for breaching their fiduciary duties to Fulgent and its shareholders.
If you are a Fulgent shareholder, you may contact attorney Joe Pettigrew for additional information toll-free at 844-818-6982 or [email protected] .
If you are a Fulgent shareholder, you may have legal claims against Fulgents directors and officers.
The firm represents pension funds, foundations, individuals, and other entities worldwide with offices in New York, London, Amsterdam, Connecticut, California, and Ohio.

DEADLINE ALERT for FLGT, YSG, BCS, and OLO: The Law Offices of Frank R. Cruz Reminds Investors of Class Actions on Behalf of Shareholders

Retrieved on:

Monday, November 21, 2022

Law, Stark Law, Genetics, IPO, Defendant, Battle of Saint-Fulgent, Anti-Kickback Statute, Suite, Investment, Remuneration, Security (finance), Mail, Holding company, Risk management, Barclays

LOS ANGELES, Nov. 21, 2022 (GLOBE NEWSWIRE) -- The Law Offices of Frank R. Cruz reminds investors that class action lawsuits have been filed on behalf of shareholders of the following publicly-traded companies.

Key Points:

LOS ANGELES, Nov. 21, 2022 (GLOBE NEWSWIRE) -- The Law Offices of Frank R. Cruz reminds investors that class action lawsuits have been filed on behalf of shareholders of the following publicly-traded companies.
Investors suffering losses on their investments are encouraged to contact The Law Offices of Frank R. Cruz to discuss their legal rights in these class actions at 310-914-5007 or by email to [email protected] .
This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.
The Law Offices of Frank R. Cruz, Los Angeles